Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Brenton G. Mar"'
Autor:
Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott F. Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K. Evans, Hui-Min Lin, Brenton G. Mar, Srdan Verstovsek, Michael W. Deininger, Jason Gotlib
Publikováno v:
Nature Medicine. 27:2183-2191
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients w
Autor:
Jason Gotlib, Andreas Reiter, Deepti H. Radia, Michael W. Deininger, Tracy I. George, Jens Panse, Alessandro M. Vannucchi, Uwe Platzbecker, Iván Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lisa K. Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M. Pettit, Mark L. Heaney, Stephen T. Oh, Jayita Sen, Hui-Min Lin, Brenton G. Mar, Daniel J. DeAngelo
Publikováno v:
Nature Medicine
Nature Medicine, 27, 2192-2199. Nature Publishing Group
Nature medicine 27(12), 2192-2199 (2021). doi:10.1038/s41591-021-01539-8
Nature Medicine, 27, 2192-2199. Nature Publishing Group
Nature medicine 27(12), 2192-2199 (2021). doi:10.1038/s41591-021-01539-8
Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltration and shortened survival. We report the results of a prespecified interim analysis of an ongoing pivotal single-arm phase 2
Autor:
Roger E. Lamoureux, Fiona Taylor, Alan L. Shields, Anthony L. Boral, Iyar Mazar, Brad Padilla, Cem Akin, Brenton G. Mar, Tanya Green, Frank Siebenhaar
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-12 (2021)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases
Background Advanced systemic mastocytosis (AdvSM), indolent systemic mastocytosis (ISM), and smoldering systemic mastocytosis (SSM) are rare diseases characterized by neoplastic mast cell infiltration of more than one organ. A content-valid patient-r
Autor:
Jeffrey G. McDonald, Frank Siebenhaar, Brad Padilla, Cem Akin, Alan L. Shields, Fiona Taylor, Anthony L. Boral, Xiaoran Li, Hui-Min Lin, Brenton G. Mar, Tanya Green
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-10 (2021)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases
Background Indolent systemic mastocytosis (ISM) is a rare, clonal mast cell neoplasm characterized by severe, unpredictable symptoms. The Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) items compose a Total Symptom Score (TSS), Gast
Autor:
Yasir Y. Elamin, Tyler Rouskin-Faust, Nicole Zhang, Teresa Green, Aditya Dhande, Brenton G. Mar, John V. Heymach, Chiara Conti
Publikováno v:
Cancer Research. 83:LB123-LB123
Background: Osimertinib, a 3rd-generation (gen) EGFR tyrosine kinase inhibitor (TKI), is standard of care in front-line (1L) patients with advanced EGFR mutant NSCLC; however, not all subgroups may benefit equally. In the phase 3 FLAURA study, patien
Autor:
Olivier Hermine, Ingunn Dybedal, Prithviraj Bose, Iván Álvarez-Twose, Ruben A. Mesa, Andreas Reiter, Jens Panse, Stephen T. Oh, Alessandro M. Vannucchi, Deepti Radia, Andrzej Mital, Cristina Bulai Livideanu, Brenton G. Mar, Hui-Min Lin, Lisa K. Hicks, Jason Gotlib, Madlen Jentzsch, Daniel J. DeAngelo, Mark L. Heaney, Jayita Sen, Lambert L.F. Span, Elizabeth O. Hexner, Michael W. Deininger, Kristen Pettit, Tracy I. George
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A90-A91
Autor:
Marie McConkey, Rob S. Sellar, Benjamin L. Ebert, John G. Doench, Siddhartha Jaiswal, Josephine Kahn, Karsten Krug, Shaunt Fereshetian, Dylan N. Adams, Shruti Bhatt, Peter Miller, Brenton G. Mar, Haoling Zhu, Christopher J. Gibson, Steven A. Carr, Alexander J. Silver, Anthony Letai, Philipp Mertins
Publikováno v:
Blood. 132:1095-1105
Truncating mutations in the terminal exon of protein phosphatase Mg2+/Mn2+ 1D (PPM1D) have been identified in clonal hematopoiesis and myeloid neoplasms, with a striking enrichment in patients previously exposed to chemotherapy. In this study, we dem
Autor:
Michael W. Deininger, Guang Yang, Brenton G. Mar, Deepti Radia, Jayita Sen, Hui-Min Lin, Jason Gotlib, Daniel J. DeAngelo, Tracy I. George
Publikováno v:
Blood. 138:318-318
Introduction: Systemic mastocytosis (SM) is a rare, hematologic neoplasm driven by KIT D816V mutations in ~95% of patients. Outcomes remain poor for patients with advanced SM (AdvSM), which comprises aggressive SM (ASM), SM with an associated hematol
Autor:
Alan L. Shields, Anthony L. Boral, Xiaoran Li, Brenton G. Mar, Brad Padilla, Jason Gotlib, Christine Yip, Tanya Green, Hui-Min Lin, Fiona Taylor, Ronny G. Oren
Publikováno v:
Leukemia Research. 108:106606
Background The Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) was developed to evaluate symptoms of advanced systemic mastocytosis (AdvSM). This study aimed to psychometrically evaluate AdvSM-SAF scores and provide score interpret
Autor:
Daniel J. DeAngelo, Olivier Hermine, Ingunn Dybedal, Hui-Min Lin, Lisa K. Hicks, Tracy I. George, Deepti Radia, Jason Gotlib, Jayita Sen, Alessandro M. Vannucchi, Lambert F.R. Span, Ruben A. Mesa, Michael W. Deininger, Prithviraj Bose, Madlen Jentzsch, Mark L. Heaney, Brenton G. Mar, Andreas Reiter, Jens Panse, Andrzej Mital, Iván Álvarez-Twose, Stephen T. Oh, Kristen Pettit, Elizabeth O. Hexner
Publikováno v:
Cancer Research. 81:CT023-CT023
Introduction: Systemic mastocytosis is a clonal, hematologic neoplasm driven by KIT D816V mutation in >90% of cases, with limited treatment options. In a phase I study, ava, a potent inhibitor of KIT D816V, induced durable responses which deepened ov